JupiteX Get the app
Health & Medicine19 Nov 2026 · about 7 min

India’s CSR spending leaves gaps in health, water security, innovation: Report

The brief

CSR, or corporate social responsibility, broadly describes how businesses contribute to social and development priorities. That general definition is background context; the report focuses on CSR funding in India. Such funding matters because it can support projects that address needs beyond a company’s own operations. The report identifies education and healthcare as the largest funding areas: they receive 35% and 21% of CSR funding, respectively. CSR projects can also support women’s economic agency, young people moving from school to work, groundwater resilience, and innovation and research. These examples come from the areas examined in the report. Funding can target different parts of a challenge, such as skilling, livelihoods, or exposure to workplaces. The report finds that the distribution within sectors matters: for every rupee spent on school-to-work transition support for academics and skilling, only 24 paise goes to workplace exposure. This points to the value of looking beyond the total amount spent and asking what activities receive support.

01

What is corporate social responsibility (CSR), and what kinds of projects can it fund?

CSR, or corporate social responsibility, broadly describes how businesses contribute to social and development priorities. That general definition is background context; the report focuses on CSR funding in India. Such funding matters because it can support projects that address needs beyond a company’s own operations.

The report identifies education and healthcare as the largest funding areas: they receive 35% and 21% of CSR funding, respectively. CSR projects can also support women’s economic agency, young people moving from school to work, groundwater resilience, and innovation and research. These examples come from the areas examined in the report.

Funding can target different parts of a challenge, such as skilling, livelihoods, or exposure to workplaces. The report finds that the distribution within sectors matters: for every rupee spent on school-to-work transition support for academics and skilling, only 24 paise goes to workplace exposure. This points to the value of looking beyond the total amount spent and asking what activities receive support.

02

How much did companies spend on CSR in India in FY25, and how concentrated was that funding?

Companies in India spent ₹40,794 crore on CSR in FY25, and annual spending had grown by 15% a year over the past decade. The total shows the scale of this source of funding. But the report also examines where the money goes, because a large overall budget does not mean every development need receives comparable attention.

Nearly 80% of CSR funding is concentrated in five sectors. Education accounts for 35% and healthcare for 21%, making them the two largest areas named in the report. The same concentration can appear within a sector: nearly 62% of identifiable NCD funding goes to cancer, while cardiovascular diseases receive around 12%.

The figures describe both growth and uneven distribution across FY23 to FY25. The report identifies funding gaps in NCDs, women’s economic agency, school-to-work transition, groundwater resilience, and innovation. Its findings suggest that assessing CSR means looking not only at how much companies spend, but also at whether that funding reaches challenges that are comparatively underfunded.

03

Which needs does the report say receive too little CSR funding compared with the scale of the challenges?

The report identifies several needs where CSR funding appears limited relative to the scale of the challenge. These include non-communicable diseases, women’s economic agency, the transition from school to work, groundwater resilience, and innovation and research. These gaps matter because the amount directed to a broad sector can hide shortfalls in particular health conditions, services, or regions.

For example, NCDs account for 60% of deaths in India, but nearly 62% of identifiable NCD funding goes to cancer. Cardiovascular diseases receive around 12%, despite accounting for over half of NCD deaths. In water resilience, Punjab, Rajasthan and Haryana contain nearly 49% of critical and over-exploited groundwater units, yet receive around 7% of identifiable CSR funding for the area.

The report also notes that only 24 paise goes to workplace exposure for every rupee spent on academic and skilling support for school-to-work transition. Women-focused funding is concentrated in skilling and livelihoods. Together, these figures point to mismatches within sectors, not simply low spending overall.

04

What can happen when funding for health, jobs, women’s economic agency or water security does not match the size of the need?

When funding does not match the size or shape of a need, some parts of a problem may receive less support than others. The report documents differences in funding, but it does not measure specific harms caused by those differences. Its figures identify where CSR resources are concentrated and where the challenges are substantial.

In health, NCDs account for 60% of deaths, yet cardiovascular diseases receive around 12% of identifiable NCD funding. For young people, 42% of school-to-work transition CSR funding supports academics and skilling, while workplace exposure receives just 24 paise for every rupee allocated to those areas. Women also face barriers including inadequate care infrastructure, unsafe mobility and limited market access.

These imbalances may make it harder for funding to address the full range of needs; that is an implication, not a measured outcome in the report. The report also does not establish what would happen if funding changed. It calls for corporates to consider whether their spending reaches problems where it can make a difference, rather than focusing only on the total amount spent.

05

What are non-communicable diseases, and why does their share of deaths matter when funding health programmes?

Non-communicable diseases, or NCDs, are generally understood as long-term health conditions that do not spread directly from one person to another. This definition is general health knowledge; the report itself focuses on cancer and cardiovascular diseases as examples. NCDs matter in the funding discussion because they account for a large share of deaths in India.

The report says NCDs made up 60% of deaths, up from 45% in 2004–06. Yet nearly 62% of identifiable CSR funding for NCDs goes towards cancer. Cardiovascular diseases receive around 12%, even though they account for over half of NCD deaths. These figures show that funding within a health category can be uneven.

The contrast matters when assessing whether programmes address the conditions contributing substantially to deaths. The report does not establish how much funding would be appropriate for each disease or what health outcomes would follow from changing allocations. It does, however, identify the difference between the share of deaths and the distribution of identifiable funding as a gap for CSR funders to consider.

06

How does India’s CSR framework shape what companies spend, and how does that spending relate to the government’s role?

The report describes CSR as a substantial and growing source of funding, but it does not explain India’s legal CSR framework. As general context beyond the article, India’s Companies Act requires certain qualifying companies to spend at least 2% of average net profits on CSR activities, with eligible activities outlined in the law. This framework influences how companies plan and report CSR spending.

The report’s figures show the scale: annual CSR spending reached ₹40,794 crore in FY25, growing 15% annually over the past decade. It also quotes Srikrishna Sridhar Murthy, co-founder and CEO of Sattva Consulting, saying CSR cannot replace government. He argues it can be patient and risk-tolerant in ways other capital often cannot.

That distinction matters: the report presents CSR as a complement, not a substitute, for government. It says patient funding can help test unproven models, build evidence about what works, and support wider adoption. The article does not specify how companies should coordinate individual projects with government programmes, but it urges them to consider whether spending reaches pressing problems.

07

What is patient, risk-tolerant funding, and how can it help test new ideas before they are scaled up?

Patient, risk-tolerant funding means support that can tolerate uncertainty and allow an idea time to be tested. The article does not provide a formal definition; it presents the idea through Sattva Consulting CEO Srikrishna Sridhar Murthy’s description of what CSR can offer. This approach matters when a proposed model has not yet been proven.

Murthy says CSR can test unproven models and build evidence on what works. In practice, that means funding can support a trial or early effort, then use what is learned to judge whether the approach merits wider adoption. The report does not name a particular model or give an example of a trial, so the mechanism here follows the steps he describes.

The report says no industry directs more than 1.2% of its total CSR spending to innovation and research, which received approximately ₹298 crore between FY23 and FY25. Murthy argues that CSR’s role can include helping successful approaches scale. The article does not claim every experiment will work; it highlights testing and evidence-building as ways CSR can use its funding.

This brief was written by AI from the original reporting and checked by other models. Names, figures and quotes come from the source; read it for full context.

Read more in the JupiteX app

Pulse is free. New stories every 4 hours, each one broken into the questions that explain it.

Or read more news on the web